Skip to content

The effect of finasteride for the treatment of melasma

Comparison of the efficacy of oral finastride and topical hydroquinone versus placebo and topical hydroquinone in treatment of melasma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016031627077N1
Enrollment
30
Registered
2016-05-28
Start date
2015-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: Control Group: In this group 15 patients received a placebo orally, along with topical hydroquinone 4% daily for three months.Monthly patients response to treatment and side effects ar
Treatment - Drugs
Control Group: In this group 15 patients received a placebo orally, along with topical hydroquinone 4% daily for three months.Monthly patients response to treatment and side effects are examined
The intervention group: The group of 15 patients with finasteride 5 mg orally on a daily basis with topical hydroquinone 4% treated on a daily basis for tree month . complications and response to trea

Sponsors

Ahwaz Jondishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patient with melasma and would like to participate in the study exclusion criteria: pregnant and lactating women, patients treated with anti androgenic drugs, oral contraceptive use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Melasma. Timepoint: Baseline, the end of the first month, the end of second month, the end of the third month. Method of measurement: By observing the amount of blur, uniformity and percentage of skin involvement in four areas of the forehead, right cheek, left cheek and chin.

Secondary

MeasureTime frame
Satisfaction with treatment. Timepoint: end of treatment. Method of measurement: Interviews with patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrjuyi Ziba

Ahwaz Jondishapoor University of Medical Sciences

Drziba2013@yahoo.com+98 61 3292 1837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026